MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases

MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases

Hepatocellular carcinomas (HCCs) are aggressive tumors with a poor prognosis. Approved first-line treatments include sorafenib, lenvatinib, and a combination of atezolizumab and bevacizumab; however, they do not cure HCC. We investigated MBP-11901 as a drug candidate for HCC. Cell proliferation and...

Full description

Bibliographic Details
Main Authors: Hyun Jin Park, Garam Choi, Seongmin Ha, Yesl Kim, Min-Jin Choi, Minsup Kim, Md. Kamrul Islam, Yongmin Chang, Tae-Jun Kwon, Dongkyu Kim, Eunbee Jang, Tae Hwan Kim, Sha Joung Chang, Yeoun-Hee Kim
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
hepatocellular carcinoma
targeted therapy
tyrosine kinase inhibitor
anticancer agent
complete response
Online Access:https://www.mdpi.com/2072-6694/14/8/1994

Internet

https://www.mdpi.com/2072-6694/14/8/1994

Similar Items